Genetically modifying autologous BMSCs for FVIII secretion for cell therapy could be a functional cure for haemophilia A. Bone marrow is an inexhaustible source of primary BMSCs which have a great capacity for ex vivo expansion. The gene discussed is F8; the disease is hemophilia A.